A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
NCT07929298, Phase 2, Not yet recruiting, Hangzhou Sciwind Biosciences Co., Ltd.
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity | ClinicalTrials.gov |
| NCT number | NCT07929298 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 180 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Hangzhou Sciwind Biosciences Co., Ltd. | ClinicalTrials.gov |
| Conditions | Overweight , Obesity, Weight Management | ClinicalTrials.gov |
| Interventions | ecnoglutide tablet, placebo with matching dosage | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Percentage Change in Body Weight | Baseline, week 24 | ClinicalTrials.gov | |
| Secondary | Percentage of Participants with ≥5% of Body Weight Loss | Baseline, week 24 | ClinicalTrials.gov | |
| Secondary | Percentage of Participants with ≥10% of Body Weight Loss | Baseline, week 24 | ClinicalTrials.gov | |
| Secondary | Percentage of Participants with ≥15% of Body Weight Loss | Baseline, week 24 | ClinicalTrials.gov | |
| Secondary | Absolute Change in Body Weight | Baseline, week 24 | ClinicalTrials.gov | |
| Secondary | Change in Body Mass Index (BMI) | Baseline, week 24 | ClinicalTrials.gov | |
| Secondary | Change in blood pressure | Baseline, week 24 | ClinicalTrials.gov | |
| Secondary | Change in other body measurements | Baseline, week 24 | Body measurements include neck circumference, waist circumference, hip circumference | ClinicalTrials.gov |
| Secondary | Change in lipid profile | Baseline, week 24 | Include triglicerides, LDL-C, HDL-C, total cholesterol | ClinicalTrials.gov |
| Secondary | Change in fasting blood glucose (FBG) | Baseline, week 24 | ClinicalTrials.gov | |
| Secondary | Change in HbA1c | Baseline, week 24 | ClinicalTrials.gov | |
| Secondary | Change in fasting insulin | Baseline, week 24 | ClinicalTrials.gov | |
| Secondary | Change in blood uric acid | Baseline, week 24 | ClinicalTrials.gov | |
| Secondary | Change in liver enzymes | Baseline, week 24 | include ALT and AST | ClinicalTrials.gov |
| Secondary | Adverse events | Week 1 to week 28 (EOS) | ClinicalTrials.gov | |
| Secondary | Plasma Concentration of Ecnoglutide | Week 1 to week 28 (EOS) | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)